{"analyses":[{"ciLowerLimit":"0.717","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.046","estimateComment":"HR with 95% confidence interval (CI) was estimated using a stratified Cox proportional hazards regression model using the Interactive Web Response System (IWRS) stratification factors (geographical regions and etiology of liver disease).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1391","paramType":"Hazard Ratio (HR)","paramValue":"0.866","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.05","upperLimit":"10.64","value":"9.17"},{"groupId":"OG001","lowerLimit":"6.01","upperLimit":"9.33","value":"7.62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"282"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the end of the follow-up period or were lost to follow-up were censored on the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG000","title":"Ramucirumab (IMC-1121B) + BSC"},{"description":"Placebo: 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) Population: All randomized participants. Participants censored: Ramucirumab+BSC (Ram)=65, Placebo+BSC (Pl)=58.","reportingStatus":"POSTED","timeFrame":"Randomization to death from any cause (up to 37 months)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}